|Videos|May 2, 2022

Other Venetoclax-based Combination Regimens Being Evaluated in Multiple Myeloma

Sponsored in Part by AbbVie/Content Independently Developed by Targeted Oncology. Jonathan Kaufman, MD, describes clinical trials looking at venetoclax resistance, including the CANOVA study.


Latest CME